It’s shaping up to be a good day for Orexigen Therapeutics Inc. (NASDAQ:OREX), Autohome Inc. (NYSE:ATHM) and American Eagle Outfitters (NYSE:AEO), which are making big climbs early. On the losing end are Veeva Systems Inc. (NYSE:VEEV), Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) and MacroGenics Inc. (NASDAQ:MGNX).
ValueWalk's Raul Panganiban interviews JP Lee, Product Managers at VanEck, and discusses the video gaming industry. Q4 2020 hedge fund letters, conferences and more The following is a computer generated transcript and may contain some errors. Interview With VanEck's JP Lee ValueWalk's ValueTalks ·
Autohome Soars on Results
Orexigen Therapeutics continues to climb, gaining +11.13% early in the day this Wednesday. The Miami-based company disclosed that one of its anti-obesity drugs has heart benefits – a move unwelcomed by the FDA. Tom Steyer’s Farallon Capital has a stake in the firm.
Autohome surged +10.68% after releasing its unaudited fourth quarter and full-year financial results. The company’s revenues accelerated significantly in Q4, and its net income for 2014 increased 64.1% year-over-year. Tiger Global has an 8.73-million-share stake in Autohome, and billionaire George Soros holds nearly a million shares of his own.
American Eagle Outfitters climbed +8.64% today after reporting upbeat first quarter guidance numbers. The apparel company said it expects earnings between nine and 12 cents per share. Ray Dalio has a small position in American Eagle.
Veeva Systems Stumbles
Veeva Systems Inc. plunged -22.55% this morning. The cloud software company largely exceeded analysts’ expectations with its latest earnings report, out yesterday, but the market is apparently unimpressed. Tiger Global has 0.02% of its equity portfolio allocated to Veeva.
Cyclacel Pharmaceuticals tumbled -19.72% after announcing a public offering of its common stock. The stock, a Wilbur Ross holding, has declined about -70% over the past year.
MacroGenics fell -6.44% in the on the heels of its earnings report. It missed the consensus estimate on its EPS by $0.33. A clinical-stage biopharmaceutical company, MacroGenics is in the investment portfolios of billionaires Julian Robertson and George Soros.